Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - diclofenac (diclofenac sodium) - tablets gastro-resistant - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.2 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: crospovidone; methacrylic acid copolymer; sodium carbonate; titanium dioxide; macrogol 8000; magnesium stearate; iron oxide yellow; lactose; triethyl citrate; purified talc; hypromellose; microcrystalline cellulose - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. - duodenal ulcer. - gastric ulcer. - gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. - reflux oesophagitis. - gastrointestinal lesions refractory to h 2-blockers. - zollinger-ellison syndrome.. patients whose gastric or duodenal ulceration is not associated with ingestion of nsaids require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.6 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid copolymer; magnesium stearate; titanium dioxide; purified talc; lactose; sodium carbonate; triethyl citrate; crospovidone; macrogol 8000; iron oxide yellow; hypromellose; microcrystalline cellulose - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. - duodenal ulcer. - gastric ulcer. - gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. - reflux oesophagitis. - gastrointestinal lesions refractory to h 2-blockers. - zollinger-ellison syndrome.. patients whose gastric or duodenal ulceration is not associated with ingestion of nsaids require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pantoprazole sodium, quantity: 45.113 mg - tablet, enteric coated - excipient ingredients: hyprolose; triethyl citrate; crospovidone; purified talc; calcium stearate; sodium lauryl sulfate; sodium carbonate; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; titanium dioxide; iron oxide yellow; hypromellose; propylene glycol; povidone; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion i.e for duodenal ulcer, gastric ulcer, gastro-oesophageal reflux disease (gord) including - symptomatic gord. the treatment of heartburn and other symptoms associated with gord; - reflux oesophagitis; gastrointestinal lesions refractory to h2 blockers, and zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pantoprazole sodium, quantity: 22.557 mg - tablet, enteric coated - excipient ingredients: purified talc; microcrystalline cellulose; sodium carbonate; sodium lauryl sulfate; iron oxide yellow; titanium dioxide; triethyl citrate; mannitol; crospovidone; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); calcium stearate; hypromellose; propylene glycol; povidone; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion i.e for duodenal ulcer, gastric ulcer, gastro-oesophageal reflux disease (gord) including - symptomatic gord. the treatment of heartburn and other symptoms associated with gord; - reflux oesophagitis; gastrointestinal lesions refractory to h2 blockers, and zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; iron oxide yellow; purified talc; peg-40 hydrogenated castor oil; methacrylic acid - ethyl acrylate copolymer (1:1); lactose monohydrate; maize starch; triethyl citrate; povidone; hypromellose; titanium dioxide - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: peg-40 hydrogenated castor oil; magnesium stearate; purified talc; povidone; sodium starch glycollate type a; hypromellose; titanium dioxide; maize starch; triethyl citrate; iron oxide red; iron oxide yellow; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; methacrylic acid - ethyl acrylate copolymer (1:1) - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: triethyl citrate; purified talc; sodium starch glycollate; magnesium stearate; maize starch; iron oxide yellow; calcium hydrogen phosphate dihydrate; methacrylic acid copolymer; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; lactose monohydrate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: maize starch; methacrylic acid copolymer; colloidal anhydrous silica; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; purified talc; triethyl citrate; iron oxide yellow; titanium dioxide; lactose monohydrate; sodium starch glycollate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: magnesium stearate; peg-40 hydrogenated castor oil; iron oxide yellow; hypromellose; purified water; microcrystalline cellulose; sodium starch glycollate type a; colloidal anhydrous silica; triethyl citrate; maize starch; purified talc; titanium dioxide; povidone; lactose monohydrate; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component.,symptomatic treatment of primary dysmenorrhoea.